Mirza Saqeb B, Campion Jon, Dixon John H, Panesar Sukhmeet S
Department of Orthopaedics, Weston General Hospital, Weston-super-Mare, Somerset, UK.
Ann R Coll Surg Engl. 2007 Nov;89(8):777-84. doi: 10.1308/003588407X209310.
Patients undergoing total hip replacement (THR) regularly receive allogenic blood transfusions. The infusion of allogenic blood exposes the recipient to significant risks including the transmission of infection, anaphylactic and haemolytic reactions. The purpose of this study was to determine the effect of introducing a system to retransfuse salvaged drainage blood in patients undergoing primary THR.
We reviewed records of 109 consecutive patients who underwent THR following the introduction of the ABTrans autologous retransfusion system at our institution in January 2000. For comparison, we reviewed the medical records of 109 patients who underwent the same procedure immediately before the introduction of the retransfusion system.
Overall, 9% of patients treated with blood salvage and 30% treated without blood salvage required allogenic blood transfusions. Patients treated with the salvage system had significantly smaller haemoglobin drops in the peri-operative period (difference 0.56 g/dl; P = 0.001). The overall cost of using the retransfusion system was similar to that of routine vacuum drainage when the savings of reduced allogenic blood transfusion were taken into account.
The retransfusion of postoperative drainage blood is a simple, effective and safe way of providing autologous blood for patients undergoing primary THR.
接受全髋关节置换术(THR)的患者经常接受异体输血。输注异体血会使受血者面临重大风险,包括感染传播、过敏和溶血反应。本研究的目的是确定在初次全髋关节置换术患者中引入回收引流血再输注系统的效果。
我们回顾了2000年1月在我们机构引入ABTrans自体再输血系统后连续接受全髋关节置换术的109例患者的记录。为作比较,我们回顾了在再输血系统引入前立即接受相同手术的109例患者的病历。
总体而言,接受血液回收治疗的患者中有9%需要异体输血,未接受血液回收治疗的患者中有30%需要异体输血。接受回收系统治疗的患者围手术期血红蛋白下降明显较小(差异为0.56 g/dl;P = 0.001)。考虑到减少异体输血节省的费用,使用再输血系统的总体成本与常规真空引流相似。
术后引流血再输注是为初次全髋关节置换术患者提供自体血的一种简单、有效且安全的方法。